A LinkedIn post from Segmed highlights an upcoming Bytes of Innovation session focused on data infrastructure for precision health. The event will feature Verily Health’s VP of Life Sciences & MedTech, Denise Meade, and will discuss how Verily’s Pre platform and Segmed’s data assets are being used together.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, Verily Exchange and Workbench are presented as creating a unified workflow from data discovery through secure analysis, while Segmed contributes real‑world imaging and multimodal data, including longitudinal breast and lung cancer cohorts. The content positions Segmed as a key data provider for pharma and biotech research, suggesting potential for deeper collaboration with large life sciences and technology partners.
For investors, this emphasis on governed, scalable data ecosystems underscores Segmed’s strategy to compete in the high‑value healthcare AI and real‑world evidence markets. Increased visibility alongside Verily, part of Alphabet Inc., may support Segmed’s business development efforts, potentially expanding its customer base in life sciences and MedTech and enhancing the company’s long‑term revenue prospects if such collaborations translate into commercial agreements.